Faeth Therapeutics, Inc.
FTHHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframeFaeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. At a $1.03B market cap, Faeth Therapeutics, Inc. ranks as a small-cap company within healthcare. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Market Cap
$1.03B
Beta
-0.28
P/E (TTM)
—
P/E (Fwd)
-8.07
EPS (TTM)
$-60.86
EPS (Fwd)
$-4.96
ROE
-195.3%
ROA
-20.8%
Cash
$186.4M
Total Debt
$592,000
Free CF
$855,125
52W Change
405.0%
Annual Financials
Cash vs Debt
Where FTH stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, FTH finished 54.32% above its 150-day moving average ($25.35) and 82.89% above its 200-day moving average ($21.39). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FTH overbought or oversold?
At the September 3, 2026 close, FTH's RSI(14) was 78.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $186.4M in cash comfortably exceeding the $592K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $855K in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -195.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of -0.28 suggests FTH is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, FTH has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing FTH.